LONZA GROUP AG Financials Lonza Group AG Deutsche Boerse AG
Equities
LO3A
US54338V1017
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.5 EUR | 0.00% |
|
+1.41% | +35.75% |
| Jun. 20 | Berenberg Lifts Price Target on Lonza Group, Maintains Buy Recommendation | MT |
| May. 14 | Swiss Market Index Edges Up Ahead of Inflation Report | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 26,224 | 42,255 | 56,574 | 33,615 | 26,273 | 34,266 | - | - |
| Enterprise Value (EV) 1 | 29,185 | 45,068 | 55,616 | 33,429 | 27,195 | 37,012 | 37,631 | 37,528 |
| P/E ratio | 40.8 x | 48.9 x | 19.3 x | 27.7 x | 39.8 x | 40.1 x | 32 x | 25.9 x |
| Yield | 0.78% | 0.53% | 0.39% | 0.66% | 1.13% | 0.92% | 1.08% | 1.24% |
| Capitalization / Revenue | 4.43 x | 6.83 x | 10.5 x | 5.4 x | 3.91 x | 5.15 x | 4.49 x | 4.01 x |
| EV / Revenue | 4.93 x | 7.29 x | 10.3 x | 5.37 x | 4.05 x | 5.56 x | 4.93 x | 4.39 x |
| EV / EBITDA | 18 x | 26.1 x | 33.4 x | 16.8 x | 13.6 x | 20.1 x | 17.2 x | 14.6 x |
| EV / FCF | 146 x | 287 x | -449 x | -39.2 x | -91.6 x | -237 x | 564 x | 111 x |
| FCF Yield | 0.69% | 0.35% | -0.22% | -2.55% | -1.09% | -0.42% | 0.18% | 0.9% |
| Price to Book | 4.03 x | 6.2 x | 5.82 x | 3.18 x | 2.76 x | 3.64 x | 3.45 x | 3.18 x |
| Nbr of stocks (in thousands) | 74,246 | 74,289 | 74,283 | 74,189 | 74,282 | 69,874 | - | - |
| Reference price 2 | 353.2 | 568.8 | 761.6 | 453.1 | 353.7 | 490.4 | 490.4 | 490.4 |
| Announcement Date | 1/21/20 | 1/27/21 | 1/26/22 | 1/25/23 | 1/26/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,920 | 6,185 | 5,409 | 6,223 | 6,717 | 6,657 | 7,626 | 8,548 |
| EBITDA 1 | 1,624 | 1,728 | 1,665 | 1,995 | 1,999 | 1,837 | 2,189 | 2,569 |
| EBIT 1 | 1,249 | 1,358 | 1,151 | 1,397 | 939 | 1,173 | 1,484 | 1,800 |
| Operating Margin | 21.1% | 21.96% | 21.28% | 22.45% | 13.98% | 17.63% | 19.47% | 21.06% |
| Earnings before Tax (EBT) 1 | 849 | 986 | 760 | 1,448 | 790 | 1,079 | 1,370 | 1,704 |
| Net income 1 | 645 | 869 | 2,944 | 1,215 | 654 | 878.4 | 1,101 | 1,359 |
| Net margin | 10.9% | 14.05% | 54.43% | 19.52% | 9.74% | 13.2% | 14.43% | 15.9% |
| EPS 2 | 8.650 | 11.63 | 39.52 | 16.34 | 8.880 | 12.22 | 15.30 | 18.90 |
| Free Cash Flow 1 | 200 | 157 | -124 | -852 | -297 | -156.4 | 66.69 | 338.1 |
| FCF margin | 3.38% | 2.54% | -2.29% | -13.69% | -4.42% | -2.35% | 0.87% | 3.96% |
| FCF Conversion (EBITDA) | 12.32% | 9.09% | - | - | - | - | 3.05% | 13.16% |
| FCF Conversion (Net income) | 31.01% | 18.07% | - | - | - | - | 6.06% | 24.88% |
| Dividend per Share 2 | 2.750 | 3.000 | 3.000 | 3.000 | 4.000 | 4.528 | 5.298 | 6.105 |
| Announcement Date | 1/21/20 | 1/27/21 | 1/26/22 | 1/25/23 | 1/26/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,944 | 3,074 | 3,111 | 2,542 | 2,867 | 2,982 | 3,241 | 3,078 | 3,639 | 3,033 | 3,662 |
| EBITDA 1 | 796 | 893 | 835 | 847 | 818 | 987 | 1,008 | 922 | 1,077 | 808.5 | 1,046 |
| EBIT 1 | 606 | 706 | 652 | 606 | 545 | 698 | 699 | 563 | 376 | 507.3 | 700.4 |
| Operating Margin | 20.58% | 22.97% | 20.96% | 23.84% | 19.01% | 23.41% | 21.57% | 18.29% | 10.33% | 16.73% | 19.13% |
| Earnings before Tax (EBT) 1 | 407 | 564 | 422 | 296 | 464 | 594 | 854 | 486 | 304 | 428.9 | 646.4 |
| Net income 1 | 346 | 477 | 392 | 319 | 2,625 | 492 | 723 | 410 | 244 | 355.4 | 532.2 |
| Net margin | 11.75% | 15.52% | 12.6% | 12.55% | 91.56% | 16.5% | 22.31% | 13.32% | 6.71% | 11.72% | 14.53% |
| EPS 2 | 4.640 | 6.390 | 5.240 | 4.280 | 35.24 | 6.610 | 9.730 | 5.540 | 3.340 | 4.853 | 7.270 |
| Dividend per Share 2 | - | - | 3.000 | 3.000 | - | - | 3.000 | 3.500 | - | 4.000 | - |
| Announcement Date | 1/21/20 | 7/24/20 | 1/27/21 | 7/23/21 | 1/26/22 | 7/22/22 | 1/25/23 | 7/21/23 | 1/26/24 | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 2,961 | 2,813 | - | - | 922 | 2,746 | 3,365 | 3,261 |
| Net Cash position 1 | - | - | 958 | 186 | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.823 x | 1.628 x | - | - | 0.4612 x | 1.495 x | 1.537 x | 1.27 x |
| Free Cash Flow 1 | 200 | 157 | -124 | -852 | -297 | -156 | 66.7 | 338 |
| ROE (net income / shareholders' equity) | 10.1% | 13.1% | 35.5% | 11.9% | 6.52% | 9.12% | 11% | 12.7% |
| ROA (Net income/ Total Assets) | 4.65% | 6.15% | 19.1% | 7.19% | 3.82% | 5.23% | 6.24% | 7.34% |
| Assets 1 | 13,884 | 14,135 | 15,444 | 16,907 | 17,103 | 16,788 | 17,642 | 18,503 |
| Book Value Per Share 2 | 87.60 | 91.70 | 131.0 | 143.0 | 128.0 | 135.0 | 142.0 | 154.0 |
| Cash Flow per Share 2 | 13.20 | 15.10 | 16.30 | 13.70 | 18.80 | 22.20 | 24.30 | 29.50 |
| Capex 1 | 786 | 973 | 1,300 | 1,872 | 1,682 | 1,600 | 1,605 | 1,605 |
| Capex / Sales | 13.28% | 15.73% | 24.03% | 30.08% | 25.04% | 24.04% | 21.04% | 18.78% |
| Announcement Date | 1/21/20 | 1/27/21 | 1/26/22 | 1/25/23 | 1/26/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
490.4
CHF
Average target price
586
CHF
Spread / Average Target
+19.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.41% | 45.51B | |
| -8.62% | 38.52B | |
| +26.95% | 30.74B | |
| -13.50% | 26.03B | |
| +10.74% | 25.92B | |
| +44.87% | 14.13B | |
| +34.36% | 12.73B | |
| -7.14% | 11.29B | |
| -12.61% | 10.64B |
- Stock Market
- Equities
- LONN Stock
- LO3A Stock
- Financials Lonza Group AG
